Авторы

  • Юнусова З.Д., Ассесорова Ю.Ю., Исламов М.С., Мустафина Л.К., Алимов Т.Р., Бобоев К.Т., Марданов А.К., Латипова Н.Р., Бергер И.В., Жуламанова Д.И.

Ключевые слова:

миелодиспластический синдром, del(5q), цитогенетическое исследование, редкие хромосомные нарушения, острый миелоидный лейкоз.

Библиографические ссылки

Auger N, Douet–Guilbert N, Quessada J, et al. Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH). Curr Res Transl Med. 2023 Oct–Dec; 71(4):1 03409. doi: 10.1016/j.retram. 2023.103409.

Bacher U, Schanz J, Braulke F, Haase D. Rare cytogenetic abnormalities in myelodysplastic syndromes. Mediterr J Hematol Infect Dis. 2015 May 1;7(1):e2015034. doi: 10.4084/MJHID.2015.034.

da Silva–Coelho P, Kroeze LI, Yoshida K, et al. Clonal evolution in myelodysplastic syndromes. Nat Commun. 2017 Apr 21; 8:1 5099. doi: 10.1038/ ncomms15099.

Dodillet H, Kreuzer KA, Monsef I, Skoetz N. Thrombopoietin mimetics for patients with myelodysplastic syndromes. Cochrane Database Syst Rev. 2017 Sep 30; 9(9): CD009883. doi: 10.1002/14651 858.CD009883.pub2.

Fenaux P, Haase D, Santini V, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow–up†☆. Ann Oncol. 2021 Feb; 32(2): 142–156. doi: 10.1016/j.annonc.2020.11.002.

Garcia–Manero G. Myelodysplastic syndromes: 2023 update on diagnosis, risk–stratification, and management. Am J Hematol. 2023 Aug; 98(8): 1307–1325. doi: 10.1002/ajh.26984. Epub 2023 Jun 8. PMID: 37288607.

Karel D, Valburg C, Woddor N, Nava VE, Aggarwal A. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape. Curr Oncol. 2024 Apr 3;31(4):1971–1993. doi: 10.3390/curroncol31040148.

McGowan–Jordan J., Simons A., Schmid M. ISCN: An international system for human cytogenomic nomenclature. Basel, New York: Karger; 2016. – 140 p.

Muto T, Walker CS, Agarwal P, et al. Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation. Haematologica. 2023 Oct 1;108(10):2715–2729. doi: 10.3324/haematol.2022.282349.

Nachtkamp K, Kobbe G, Gattermann N, Germing U. Myelodysplastic Syndromes: New Methods of Diagnosis, Prognostication, and Treatment. Dtsch Arztebl Int. 2023 Mar 24;120(12):203–210. doi: 10.3238/arztebl.m2023.0005.

Sekeres MA, Taylor J. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review. JAMA. 2022 Sep 6;328(9):872–880. doi: 10.1001/ jama. 2022.14578.

Shao H, Cen J, Chen S, et al. Myeloid neoplasms with t(12;22)(p13;q12)/MN1–EVT6: a systematic review of 12 cases. Ann Hematol. 2018 Mar; 97(3):417–424. doi: 10.1007/s00277–017–3208–2. Epub 2017 Dec 22. PMID: 29273914.

Shao H, Yang Q, Gong Y, et al. [Molecular cytogenetic characterization of five patients with myeloid leukemia and t(12;22)(p13;q12)]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2019 Feb 10; 36(2): 112–115. Chinese. doi: 10.3760/cma.j.issn.1003–9406.2019.02.004.

Swerdlow S.H., Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC) / ed. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H T.J. 2017. 585 p.

Vu MP, Ha HQ, Nguyen CN. Cytogenetic characteristics in Vietnamese patients diagnosed with primary myelodysplastic syndromes. Leuk Res Rep. 2022 Aug 12;18:100343. doi: 10.1016/j.lrr. 2022.100343.

Wu J, Zhang Y, Qin T, et al. IPSS–M has greater survival predictive accuracy compared with IPSS–R in persons ≥ 60 years with myelodysplastic syndromes. Exp Hematol Oncol. 2022 Oct 17; 11(1) :73. doi: 10.1186/s40164–022–00328–4.

Yang L, Qian Y, Eksioglu E, et al. The inflammatory microenvironment in MDS. Cell Mol Life Sci. 2015 May;72(10):1959–66. doi: 10.1007/s000 18–015–1846–x.

Zahid MF, Malik UA, Sohail M, et al. Cytogenetic Abnormalities in Myelodysplastic Syndromes: An Overview. Int J Hematol Oncol Stem Cell Res. 2017 Jul 1;11(3):231–239.